Milestone Scientific reported strong Q2 2026 financial results, with overall revenue increasing by 22% and its medical segment experiencing significant 231% growth. The company also announced key strategic developments, including a distribution agreement with Red One Medical and third-party validation for its CompuFlo technology, indicating positive momentum despite a projected Q3 sequential revenue decline.
Milestone Scientific (MLSS) announced a robust Q2 2026, with total revenue up 22% and its medical segment, driven by CompuFlo, surging 231%. This growth is supported by favorable Medicare reimbursements, an expanding advisor program, and a new distribution agreement with Red One Medical targeting federal healthcare. The company also achieved significant third-party clinical validation for CompuFlo, which could accelerate adoption. While Q3 is projected to see a sequential decline due to non-recurring international orders and seasonality, the reaffirmed full-year guidance and strategic advancements suggest long-term positive momentum, particularly in the medical segment. Traders should watch for continued medical segment growth and the impact of new distribution channels.